Product Name:
p38a-pT180+pY182
Product Number:
ab-pk739
Target Full Name: Mitogen-activated protein-serine kinase p38 alpha; Mitogen-activated protein kinase 14
Target Alias: CSAID Binding protein 1; CSBP1; CSBP2; EXIP; MAP kinase MXI2; MAPkinase p38alpha; MAPK14; p38 ALPHA; p38 MAP kinase; p38 mitogen activated protein kinase; RK; SAPK 2A; Stress activated protein kinase 2A
Product Type Specific: p38-alpha MAPK (MAPK14) protein kinase phosphosite-specific antibody
Antibody Code: PK739
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T180+Y182
Protein UniProt: Q16539
Protein SigNET: p38a
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human p38a MAPK (MAPK14) sequence peptide Cat. No.: PE-04ADS75
Antibody Immunogen Sequence: DEM(pT)G(pY)(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues D177 to Y182; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T180 and Y182 phosphorylation is stimulatory for phosphotransferase activity. These are two of the major in vivo phosphorylation sites in p38a (≥1578 and ≥3744 reports, respectively, by mass spectrometry). p38a MAPK is known to be phosphorylated in vitro at T180 by ASK1 (MAP3K5), MEKK6 (MAP3K6, ASK2), MKK3 (MAP2K3, MEK3), MKK4 (MAP2K4, MEK4), MKK6 (MAP2K6, MEK6), p38a MAPK (MAPK14), and PBK (TOPK), and at Y182 by ASK1 (MAP3K5), MEKK6 (MAP3K6, ASK2), MKK3 (MAP2K3, MEK3), MKK4 (MAP2K4, MEK4), MKK6 (MAP2K6, MEK6), p38a MAPK (MAPK14), PBK (TOPK), and Ret.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Platypus | Chicken | Frog | Zebra fish | Fruit fly | Honey bee | Nematode worm.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 38-43 kDa.
Antibody Specificity: Medium-High
Antibody Cross Reactivity: No immunoreactivity with recombinant human p38a, p38b, p38d or p38g. High background with antibody in HepG2 cells. In Jurkat cells, phenylarsine oxide (PAO) increases detection of 15 kDa protein.
Related Product 1: p38a (177-182) pT180+pY182 antibody blocking peptide (Cat. No.: PE-04ADS75)
Related Product 2: p38SelectideA kinase substrate peptide (Cat. No.: PE-14CAC90)
Related Product 3: p38Subtide kinase substrate peptide (Cat. No.: PE-01BIK99)
Related Product 4: p38a expression antibody (Cat. No.: AB-NK120-10)
Related Product 5: p38 alpha (MAP Kinase) expression antibody (Cat. No.: AB-NK120-4)
Related Product 6: p38 expression antibody (Cat. No.: AB-NK120-5)
Related Product 7: p38a expression antibody (Cat. No.: AB-NK120-8)
Related Product 8: p38a T180+Y182 phosphorylation antibody (Cat. No.: AB-PK739)
Scientific Background: The MAPK (mitogen activated protein kinase) comprises a family of ubiquitous praline-directed, proteinserine/ threonine kinases which signal transduction pathways that control intracellular events including acute responses to hormones and major developmental changes in organisms (1). This super family consists of stress activated protein kinases (SAPKs); extracellular signal-regulated kinases (ERKs); and p38 kinases, each of which forms a separate pathway (2). The kinase members that populate each pathway are sequentially activated by phosphorylation. Phosphorylation at T180 and Y182 increases its phosphotransferase activity. These phospho-sites are targeted by MKK3 (MAP2K3), MKK6 (MAP2K6), and potentially also MKK4 (MAP2K4). Phosphorylation at Y323 also increases its phosphotransferase activity. It is inhibited by dual specificity phosphatases, such as DUSP1. Phosphorylation at T123 inhibits phosphotransferase activity and interaction with MKK6 and MAPKAPK2. Upon activation, p38 MAPK/SAPK2α translocates into the nucleus where it phosphorylates one or more nuclear substrates, effecting transcriptional changes and other cellular processes involved in cell growth, division, differentiation, inflammation, and death (3). Specifically p38 always acts as a pro-apoptotic factor with its activation leading to the release of cytochrome c from mitochondria and cleavage of caspase 3 and its downstream effector, PARP (4). p38 MAPK is activated by a variety of chemical stress inducers including hydrogen peroxide, heavy metals, anisomycin, sodium salicylate, LPS, and biological stress signals such as tumour necrosis factor, interleukin-1, ionizing and UV irradiation, hyperosmotic stress and chemotherapeutic drugs (5). As a result, p38 alpha has been widely validated as a target for inflammatory disease including rheumatoid arthritis, COPD and psoriasis (6) and has also been implicated in cancer, CNS and diabetes (7). Its many substrates include the transcription regulators ATF2, MEF2C, and MAX; the cell cycle regulator CDC25B; and p53, which indicates that p38a plays a role in stress-related transcription and in cell cycle regulation, as well as in the genotoxic stress response. It is a key player in the maintenance of hematopoiesis homeostasis, as it balances both proliferative and growth inhibitory signals from growth factors/cytokines that regulate hematopoiesis. Alterations in this controlled balance could result in either overproduction or depletion of myelosuppressive cytokines, which could lead to the development of various types of bone marrow failures. p38a may be also involved in drug resistance development of acute myeloid leukemias. This description may include information annotated by UniProt and/or Google AI.